Acute Graft-Versus-Host Disease Biomarkers Measured During Therapy Can Predict Treatment Outcomes: A Blood and Marrow Transplant Clinical Trials Network Study. Blood, 119, 3854-3860. presented at the 04/2012.. (2012).
Grade III - IV Acute GvHD and Treatment-Related Mortality Are Reduced Among Recipients of Larger Numbers of Donor Naïve CD8+ T-cells and Plasmacytoid Dendritic Cell Precursors in Allogeneic BM Grafts from Unrelated Donors: Results from BMT CTN 0201. In 38th Annual EBMT (European Group for Blood and Marrow Transplantation). presented at the 01/04/2012, Geneva, Switzerland. Retrieved from http://www.congrex.ch/ebmt2012.html. (2012).
Blood and Marrow Transplant Clinical Trials Network (BMT CTN): Addressing Unanswered Questions. Biol Blood Marrow Transplant, 13, 257-262. presented at the 03/2007. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/17317578. (2007).
Blood and Marrow Transplant Clinical Trials Network Toxicity Committee Consensus Summary: Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant, 11, 571-575. presented at the 08/2005. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/16041306. (2005).